MX2023004712A - Compuestos moduladores del cftr, composiciones y usos de estos. - Google Patents

Compuestos moduladores del cftr, composiciones y usos de estos.

Info

Publication number
MX2023004712A
MX2023004712A MX2023004712A MX2023004712A MX2023004712A MX 2023004712 A MX2023004712 A MX 2023004712A MX 2023004712 A MX2023004712 A MX 2023004712A MX 2023004712 A MX2023004712 A MX 2023004712A MX 2023004712 A MX2023004712 A MX 2023004712A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
methods
treating
cftr
Prior art date
Application number
MX2023004712A
Other languages
English (en)
Inventor
Jung Woo Lee
Kyung Mi An
Jin Hee Lee
Te-Ik Sohn
Changmok Oh
Gunhee Kim
Yearin Jun
Myongjae Lee
Dami Lim
Kyeong-A Kim
Seolhee Lee
Ilji Jeong
Jaeeun Ryu
Jooyun Lee
Jinsun Kwon
Jungho Kim
Jongmin Yoon
Hongchul Yoon
Joontae Park
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of MX2023004712A publication Critical patent/MX2023004712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan compuestos moduladores de CFTR y composiciones que incluyen dichos compuestos. La presente divulgación también proporciona compuestos inhibidores de PDE4 y composiciones que incluyen dichos compuestos. También se proporcionan métodos para utilizar dichos compuestos y composiciones para modular CFTR, métodos para tratar una enfermedad o trastorno ocular y métodos para tratar indicaciones relacionadas con CFTR. La presente divulgación también proporciona métodos para utilizar dichos compuestos y composiciones para inhibir la PDE4, para tratar una enfermedad o trastorno inflamatorio y para tratar otras indicaciones relacionadas con la PDE4. También se proporcionan métodos de preparación de dichos compuestos y composiciones, y precursores sintéticos de dichos compuestos.
MX2023004712A 2020-10-23 2021-10-22 Compuestos moduladores del cftr, composiciones y usos de estos. MX2023004712A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104979P 2020-10-23 2020-10-23
PCT/IB2021/000710 WO2022084741A1 (en) 2020-10-23 2021-10-22 Cftr modulator compounds, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004712A true MX2023004712A (es) 2023-05-09

Family

ID=81290147

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004712A MX2023004712A (es) 2020-10-23 2021-10-22 Compuestos moduladores del cftr, composiciones y usos de estos.

Country Status (15)

Country Link
US (1) US11827640B2 (es)
EP (1) EP4232451A1 (es)
JP (1) JP2023547389A (es)
KR (1) KR20230096026A (es)
CN (1) CN116348468A (es)
AR (1) AR123884A1 (es)
AU (1) AU2021363703A1 (es)
CA (1) CA3196061A1 (es)
CL (1) CL2023001139A1 (es)
CO (1) CO2023006647A2 (es)
IL (1) IL302247A (es)
MX (1) MX2023004712A (es)
TW (1) TW202233620A (es)
UY (1) UY39482A (es)
WO (1) WO2022084741A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380835B (zh) * 2022-01-06 2022-12-27 南京桦冠生物技术有限公司 一种7-(3,4-二甲氧苯基)-2-吡唑[1,5-a]嘧啶羧酸的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178449A (en) 1978-04-17 1979-12-11 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines
US4281000A (en) 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
US5688949A (en) 1991-04-22 1997-11-18 Otsuka Pharmaceutical Factory, Inc. Pyrazolo 1,5-A!pyrimidine derivatives and anti-inflammatory agent containing the same
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
JPWO2005037837A1 (ja) * 2003-10-17 2006-12-28 日本化薬株式会社 置換２−アミノ−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体及びその用途
JP2007517876A (ja) 2004-01-14 2007-07-05 マリンクロッド・インコーポレイテッド 選択的ピラゾロピリミジン類の合成のための２相法
KR20070045254A (ko) 2004-08-02 2007-05-02 슈바르츠 파르마 악티엔게젤샤프트 인돌리진 카르복사미드 및 그 아자 및 디아자유도체
WO2006088246A1 (ja) 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
AU2006305104B2 (en) 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2012000970A1 (en) 2010-07-01 2012-01-05 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US8883789B2 (en) * 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CN103923105B (zh) 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
CN108699107B (zh) 2015-12-24 2022-05-10 加利福尼亚大学董事会 Cftr调节剂及其使用方法
CN107286156A (zh) 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
WO2018145080A1 (en) * 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Also Published As

Publication number Publication date
EP4232451A1 (en) 2023-08-30
UY39482A (es) 2022-05-31
CO2023006647A2 (es) 2023-05-29
US11827640B2 (en) 2023-11-28
AU2021363703A1 (en) 2023-06-22
TW202233620A (zh) 2022-09-01
CL2023001139A1 (es) 2023-11-17
CA3196061A1 (en) 2022-04-28
JP2023547389A (ja) 2023-11-10
AR123884A1 (es) 2023-01-18
CN116348468A (zh) 2023-06-27
IL302247A (en) 2023-06-01
WO2022084741A1 (en) 2022-04-28
US20230080486A1 (en) 2023-03-16
KR20230096026A (ko) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2021010198A (es) Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
UY38685A (es) Moduladores de la vía de tensión integrada
MX2021003819A (es) Moduladores de alfa-1 antitripsina.
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
PH12017502012A1 (en) Tricyclic sulfones as rory modulators
MX2010002674A (es) Moduladores de gamma secretasa.
MX2020008767A (es) Disruptores del dímero egfr y uso de estos.
MX2020008106A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2019009555A (es) Aminotriazolopiridinas como inhibidores de cinasa.
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
MX2021007503A (es) Moduladores de la expresion de hsd17b13.
CR20210615A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
MX2010005028A (es) Moduladores de gamma secretasa.
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MX2021008460A (es) Composición probiótica a base de esporas para modulación de propiedades dérmicas y subdérmicas.
WO2020021477A3 (en) Compositions and methods for treating the eye
MX2021009694A (es) Compuestos biciclicos sustituidos como moduladores del receptor farnesoide x.
WO2020106461A3 (en) Anti-mertk antibodies and methods of use thereof
EA202190759A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
CR20200631A (es) Modulares de la expresión de apol1
MX2023004870A (es) Moduladores de la via integrada del estres.